MyFinsight
Home
Blog
About
Contact
Download
Download image
Net change in cash
-$4,538,899
Accounts payable and
accrued expenses
$1,402,837
Change in fair value of
warrant liabilities
$279,161
Share-based compensation
expense
$134,324
Depreciation
$4,781
Net cash used in
operating activities
-$4,083,173
Net cash provided by
financing activities
-$455,726
Canceled cashflow
$1,821,103
Net loss
-$4,856,051
Payments of deferred
offering costs
$455,726
Prepaid expenses and
other current assets
$1,026,051
Grants receivable
$22,174
Back
Back
Cash Flow
source: myfinsight.com
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)